Is heritable genome editing compatible with equality in an inclusive society?
By Scottish Council on Human Bioethics,
Science Animated
| 07. 15. 2022
Heritable genome editing is being increasingly viewed as socially and morally acceptable so long as certain criteria are met. However, even despite these criteria, heritable genome editing may be in conflict with a progressive and inclusive society where all persons are considered equal. In this short animation, the Scottish Council on Human Bioethics presents philosophical arguments explaining why heritable genome editing may be at odds with equality in an inclusive society.
Watch the video here.
Additional Information: https://www.schb.org.uk/
Articles
Calum MacKellar. (2019) Genome Modifying Reproductive Procedures and their Effects on Numerical Identity, The New Bioethics 25:2, pages 121-136: https://www.tandfonline.com/doi/full/10.1080/20502877.2019.1606150
Calum MacKellar. (2021) Why human germline genome editing is incompatible with equality in an inclusive society. The New Bioethics 27:1, pages 19-29: https://www.tandfonline.com/doi/full/10.1080/20502877.2020.1869467
Robert Sparrow. (2019) Human Germline Genome Editing: On the Nature of Our Reasons to Genome Edit, Published online: 19 Apr 2021, The American Journal of Bioethics: https://www.tandfonline.com/doi/full/10.1080/15265161.2021.1907480
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...